Literature DB >> 2327208

[Damage in the hemato-enteral barrier in experimental liver transplantation].

M Simić, R Vuković, M Fabri.   

Abstract

Semiquantitative analyzes of intestinal mucous lesion graduating from 0 (normal) to V (necrotic) were done in the experimental model, 6-12h alter the heterotopic liver transplantation in dogs. All degrees of mucous damages were found in intestinal samples (mean value was 2.60). The most dominant were the lesions of III (31%) and IV (25%) degree while in 4% complete destruction of mucousal villious was observed. Success of liver transplantation besides the presence of the lesions of hepatic alograft during the phases of the warm and cold ischemia or immunological responses, depends on the changes in functionally connected regions. In that sense the damages of mesenterial department lead a very important role. Lumenal infective agents and cardiodepressive macromolecules, passing trough the hematoenteral barrier, cause local hepatic damages and central cardiovascular failure.

Entities:  

Mesh:

Year:  1990        PMID: 2327208

Source DB:  PubMed          Journal:  Acta Chir Iugosl        ISSN: 0354-950X


  2 in total

1.  Impact of vasoactive intestinal polypeptide and gastrin-releasing peptide on small bowel microcirculation and mucosal injury after hepatic ischemia/reperfusion in rats.

Authors:  Ingo Leister; J Sydow; T Stojanovic; L Füzesi; B Sattler; M Heuser; H Becker; P M Markus
Journal:  Int J Colorectal Dis       Date:  2004-07-27       Impact factor: 2.571

2.  Pretreatment with a Phosphodiesterase-3 Inhibitor, Milrinone, Reduces Hepatic Ischemia-Reperfusion Injury, Minimizing Pericentral Zone-Based Liver and Small Intestinal Injury in Rats.

Authors:  Shinichi Nakanuma; Hidehiro Tajima; Hiroyuki Takamura; Seisho Sakai; Ryosuke Gabata; Mitsuyoshi Okazaki; Hiroyuki Shinbashi; Yoshinao Ohbatake; Isamu Makino; Hironori Hayashi; Tomoharu Miyashita; Sachio Fushida; Tetsuo Ohta
Journal:  Ann Transplant       Date:  2020-07-14       Impact factor: 1.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.